Overview
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
Status:
Completed
Completed
Trial end date:
2012-06-01
2012-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Allergan
Criteria
Inclusion Criteria:- facial erythema associated with rosacea on both sides of the face
Exclusion Criteria:
- Laser light-source or other energy based therapy in the last 6 months
- Excessive hair around the treatment area